SRI-31277 is a thrombospondin 1 (TSP-1) inhibitor with a human target pIC50 of 8.28 nM and in vivo activity, and exhibits a very short plasma half-life with intravenous administration.SRI-31277 inhibits interaction between TSP-1 and the latency-associated peptide (LAP) of latent TGF-beta, blocking TSP-1-mediated TGF-beta activation.SRI-31277 can be used for the research of multiple myeloma and fibrotic conditions[1].
Molekulargewicht:
387.47
CAS Nummer:
[1637468-93-9]
Formel:
C17H33N5O5
Target-Kategorie:
TGF-beta Receptor
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
